Evaluating the effect of melatonin compared to duloxetine in the treatment of chemotherapy-induced neuropathy (CINP): a clinical trial

Evaluating the effect of melatonin compared to duloxetine on improvement of neuropathy symptoms of chemotherapy-induced neuropathy (CINP): a Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211028052893N1

Enrollment

Registered

2024-08-05

Start date

2024-09-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced neuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: Patients receiving melatonin medication. Intervention 2: Control group: Patients receiving duloxetine.

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Having solid cancer age 15 to 75 years receiving chemotherapy drugs presence of sensory neuropathy symptoms absence of neuropathy before starting chemotherapy

Exclusion criteria

Exclusion criteria: Diseases that cause sensory neuropathy such as diabetes untreated hypothyroidism sensitivity to medication (melatonin or duloxetine)

Design outcomes

Primary

Measure	Time frame
Severity of neuropathy. Timepoint: End of each week until the sixth week. Method of measurement: with the WHO grading questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Vakili

Babol University of Medical Sciences

mvakili89@gmail.com+98 11 3223 8303

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026